Globe Life (NYSE:GL) Given New $190.00 Price Target at Keefe, Bruyette & Woods

Globe Life (NYSE:GL) had its price objective trimmed by Keefe, Bruyette & Woods from $192.00 to $190.00 in a research note published on Friday morning,Benzinga reports. The firm currently has an outperform rating on the stock.

Several other research analysts also recently commented on GL. Morgan Stanley raised their price objective on Globe Life from $181.00 to $208.00 and gave the stock an “overweight” rating in a report on Monday, July 6th. JPMorgan Chase & Co. lifted their price objective on shares of Globe Life from $181.00 to $201.00 and gave the stock an “overweight” rating in a research report on Tuesday. Wells Fargo & Company raised their price objective on Globe Life from $172.00 to $193.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. Piper Sandler lifted their price objective on shares of Globe Life from $175.00 to $200.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 15th. Finally, Truist Financial raised their target price on Globe Life from $180.00 to $185.00 and gave the stock a “buy” rating in a research note on Friday, April 24th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $187.40.

Globe Life Trading Up 1.5%

GL stock opened at $173.64 on Friday. Globe Life has a twelve month low of $127.85 and a twelve month high of $191.55. The stock has a market capitalization of $13.48 billion, a price-to-earnings ratio of 11.53 and a beta of 0.47. The company has a quick ratio of 0.07, a current ratio of 0.07 and a debt-to-equity ratio of 0.38. The firm’s fifty day simple moving average is $169.07 and its two-hundred day simple moving average is $152.91.

Globe Life (NYSE:GL) last released its earnings results on Wednesday, July 22nd. The company reported $3.61 EPS for the quarter, missing analysts’ consensus estimates of $3.67 by ($0.06). Globe Life had a net margin of 19.58% and a return on equity of 20.73%. The business had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.59 billion. During the same period in the prior year, the company posted $3.05 EPS. The company’s quarterly revenue was up 8.0% compared to the same quarter last year. Globe Life has set its FY 2026 guidance at 15.550-15.950 EPS. As a group, analysts anticipate that Globe Life will post 15.67 earnings per share for the current year.

Globe Life Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Monday, July 6th will be issued a $0.33 dividend. This represents a $1.32 annualized dividend and a yield of 0.8%. The ex-dividend date is Monday, July 6th. Globe Life’s payout ratio is presently 9.13%.

Insider Activity

In other Globe Life news, CEO James Matthew Darden sold 4,663 shares of the business’s stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $153.88, for a total transaction of $717,542.44. Following the sale, the chief executive officer directly owned 58,451 shares in the company, valued at $8,994,439.88. This represents a 7.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Thomas Peter Kalmbach sold 7,936 shares of the company’s stock in a transaction dated Friday, May 22nd. The stock was sold at an average price of $156.59, for a total value of $1,242,698.24. Following the sale, the chief financial officer owned 50,496 shares in the company, valued at approximately $7,907,168.64. This trade represents a 13.58% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 90,187 shares of company stock worth $14,299,874 over the last quarter. 2.11% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Globe Life

Large investors have recently bought and sold shares of the business. Compound Planning Inc. raised its stake in Globe Life by 4.3% in the 4th quarter. Compound Planning Inc. now owns 1,968 shares of the company’s stock worth $275,000 after acquiring an additional 82 shares during the last quarter. Root Financial Partners LLC grew its stake in Globe Life by 23.3% during the 1st quarter. Root Financial Partners LLC now owns 439 shares of the company’s stock worth $61,000 after purchasing an additional 83 shares in the last quarter. Transcend Capital Advisors LLC increased its holdings in Globe Life by 3.9% during the 4th quarter. Transcend Capital Advisors LLC now owns 2,265 shares of the company’s stock worth $317,000 after purchasing an additional 84 shares during the period. Natural Investments LLC increased its holdings in Globe Life by 2.6% during the 4th quarter. Natural Investments LLC now owns 3,452 shares of the company’s stock worth $482,000 after purchasing an additional 87 shares during the period. Finally, Parallel Advisors LLC raised its position in Globe Life by 5.6% in the 4th quarter. Parallel Advisors LLC now owns 1,651 shares of the company’s stock valued at $231,000 after purchasing an additional 87 shares in the last quarter. Hedge funds and other institutional investors own 81.61% of the company’s stock.

Globe Life News Roundup

Here are the key news stories impacting Globe Life this week:

• Positive Sentiment: Keefe, Bruyette & Woods trimmed its price target only modestly to $190 from $192 and kept an outperform rating, implying roughly 9% upside from recent levels. Benzinga article
• Positive Sentiment: TD Cowen also reiterated a bullish view, forecasting strong price appreciation for Globe Life (GL). American Banking News article
• Positive Sentiment: Management raised its 2026 net operating EPS guidance to $15.55-$15.95 and lifted share repurchases to $670 million-$700 million, signaling confidence in future earnings and capital returns. Seeking Alpha article
• Neutral Sentiment: Globe Life’s Q2 revenue came in roughly in line with expectations, and underwriting income remained strong, showing the core business is still performing acceptably despite some headwinds. Reuters article
• Negative Sentiment: Q2 earnings of $3.61 per share missed the consensus estimate of $3.67, and several reports pointed to softer sales and rising expenses as reasons for investor concern. MSN article

Globe Life Company Profile

Globe Life, traded on the NYSE under the symbol GL, is a U.S.-based insurance holding company that underwrites and distributes a range of life and supplemental health insurance products. Through its subsidiary brands—Globe Life, American Income Life, Liberty National Life, United American Insurance Company and Family Heritage Life—it offers term life, whole life, fixed annuities and supplemental health coverage designed to meet the needs of individuals and families across various socioeconomic segments.

The company’s product suite includes low-cost, easy-to-understand life insurance policies, accidental death and dismemberment coverage, hospital indemnity plans and specified disease insurance.